Posard Matthew L.'s Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Jun 13, 2024
- Accession no.
- 0001415889-24-016672
- Filed
- Jun 13, 2024
- Trade date
- Jun 11-12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.01M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Posard Matthew L.CIK 0001543792 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | Common Stock | SSaleDisposed | −10,000 | $50.01 | −$500,100 | 109,755 | Direct | |
| Jun 12, 2024 | Common Stock | SSaleDisposed | −10,000 | $50.62 | −$506,200 | 99,755 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.